thiamine-disulfide and Acquired-Immunodeficiency-Syndrome

The highly conserved and mutationally intolerant retroviral zinc finger motif of the HIV-1 nucleocapsid protein (NC) is an attractive target for drug therapy due to its participation in multiple stages of the viral replication cycle. A literature search identified cystamine, thiamine disulfide, and disulfiram as compounds that have been shown to inhibit HIV-1 replication by poorly defined mechanisms and that have electrophilic functional groups that might react with the metal-coordinating sulfur atoms of the retroviral zinc fingers and cause zinc ejection. 1H NMR studies reveal that these compounds readily eject zinc from synthetic peptides with sequences corresponding to the HIV-1 NC zinc fingers, as well as from the intact HIV-1 NC protein. In contrast, the reduced forms of disulfiram and cystamine, diethyl dithiocarbamate and cysteamine, respectively, were found to be ineffective at zinc ejection, although cysteamine formed a transient complex with the zinc fingers. Studies with HIV-1-infected human T-cells and monocyte/macrophage cultures revealed that cystamine and cysteamine possess significant antiviral properties at nontoxic concentrations, which warrant their consideration as therapeutically useful anti-HIV agents.

Topics: Acquired Immunodeficiency Syndrome; Amino Acid Sequence; Anti-HIV Agents; Capsid; Capsid Proteins; Cells, Cultured; Cystamine; Disulfiram; Ditiocarb; gag Gene Products, Human Immunodeficiency Virus; Gene Products, gag; Humans; Magnetic Resonance Spectroscopy; Molecular Sequence Data; Thiamine; Viral Proteins; Zinc Fingers